Investment Rating - The report maintains an "Outperform" rating for Laopu Gold [2][3] Core Views - Laopu Gold issued a positive profit alert for 2025, expecting revenue of RMB 27.0-28.0 billion, representing a year-on-year growth of 217%-229%, and net profit of RMB 4.8-4.9 billion, reflecting a growth of 226%-233% [3][9] - The company continues to strengthen its leadership in the high-end gold jewelry segment, with strong sales performance expected in 1Q26 due to brand influence, product innovation, and channel expansion [4][10] - Despite a high base, Laopu Gold is projected to maintain strong growth in the second half of 2025, with revenue of approximately RMB 14.65-15.65 billion and net profit of approximately RMB 2.53-2.63 billion, indicating robust brand momentum and consumer demand [3][9] Financial Summary - Revenue and net profit projections for Laopu Gold are as follows: - 2025 Revenue: RMB 26,964 million, up 217% YoY - 2025 Net Profit: RMB 4,630 million, up 214% YoY - 2026 Revenue: RMB 36,035 million, up 34% YoY - 2026 Net Profit: RMB 6,508 million, up 41% YoY - 2027 Revenue: RMB 43,776 million, up 21% YoY - 2027 Net Profit: RMB 8,189 million, up 26% YoY [2][3] Valuation - The target price for Laopu Gold is set at HKD 813.6, implying a 20.5% upside based on a 2026E PE valuation of 19.5x [3][9]

Investment Rating - The report maintains an "Outperform" rating for Huali Industrial Group, with a target price of RMB 56.50, representing a potential upside of 17.6% from the current price of RMB 48.05 [2][3]. Core Insights - Huali Group's revenue for 2025 was RMB 24.98 billion, a year-on-year increase of 4.1%, which was below the forecast of 4.9%. The net profit attributable to shareholders decreased by 16.5% year-on-year to RMB 3.21 billion [3][8]. - In 4Q25, revenue was RMB 6.3 billion, down 3.0% year-on-year, with net profit attributable to shareholders at RMB 770 million, a decline of 22.6% year-on-year. The performance was impacted by cautious ordering from brands like Converse and Vans [3][8]. - Despite short-term revenue pressures, there are early signs of operational recovery, with an improvement in operating margin to 17.0% in 4Q25, indicating a recovery in operational efficiency as new capacity ramps up [3][8]. Financial Summary - Revenue projections for Huali Group are as follows: RMB 25.17 billion for 2025, RMB 27.11 billion for 2026, and RMB 29.90 billion for 2027, reflecting growth rates of 5%, 8%, and 10% respectively [2][7]. - Net profit estimates are RMB 3.39 billion for 2025, RMB 3.88 billion for 2026, and RMB 4.38 billion for 2027, with corresponding growth rates of -12%, 15%, and 13% [2][7]. - The diluted EPS is projected to be RMB 2.90 for 2025, RMB 3.33 for 2026, and RMB 3.76 for 2027 [2][7]. Operational Outlook - Looking ahead to 2026, the visibility of net margin improvement has increased, with expected contributions from key customers such as Adidas, On, and New Balance. Sales volume is projected to reach 227 million pairs, up 1.6% year-on-year, with an average selling price of RMB 110 per pair, up 2.4% year-on-year [4][9]. - The ramp-up of new factories is expected to proceed smoothly, with only one new factory planned for 2026, which should ease capacity disruptions and improve operational metrics [4][9].

Investment Rating - The report maintains a "NEUTRAL" rating for NIO Inc. with a target price of HK$51.12, based on a current price of HK$43.50 [2][6]. Core Insights - NIO turned profitable in 4Q25 for the first time on a quarterly basis, with revenue of RMB34.65 billion, representing a year-over-year increase of 75.9% and a quarter-over-quarter increase of 59% [3][11]. - Vehicle sales revenue reached RMB31.6 billion, up 80.9% year-over-year, with vehicle deliveries totaling 124.8k units, marking a new quarterly high [3][11]. - The overall gross margin improved to 17.5%, up 5.8 percentage points year-over-year, while the vehicle gross margin reached 18.1%, up 5.0 percentage points year-over-year [3][11]. - The company reported a Non-GAAP operating profit of RMB1.25 billion and a Non-GAAP net profit of RMB727 million, marking a significant turnaround from losses a year ago [3][11]. Revenue and Profitability Forecast - For 2026, NIO expects delivery growth of 40% to 50% year-over-year, with a focus on the high-end battery electric vehicle (BEV) segment [4][12]. - The company anticipates that the gross margin will remain stable in 1Q, despite cost pressures from chips and raw materials [4][12]. - Revenue forecasts for 2026-2028 are revised to RMB129.1 billion, RMB151.8 billion, and RMB164.1 billion, respectively [6][14]. Product Development and Market Position - NIO is entering a dense product cycle in 2026, with technology upgrades and new model launches, including the ES9 and L80 [5][13]. - The product lineup will cover a price range of RMB200k to RMB600k, focusing on large SUVs and intelligent features [5][13]. - Management believes that leveraging platform technology and component reuse will support delivery growth while maintaining healthy margins [5][13]. Valuation - The report assigns a 2026 EV/Sales multiple of 1.3x, leading to a target price of HK$51.12, reflecting the company's entry into a strong product cycle [6][14].

Investment Rating - The report maintains an "OUTPERFORM" rating for Softcare, with a target price of HK$35.10, representing approximately 16.2% upside potential from the current price of HK$31.26 [2][3]. Core Insights - Softcare is positioned as a leading player in the essential consumer goods market in Africa, with a dual-track model of "Localization + Distribution" that creates a competitive moat and replicable growth strategy [1][3]. - The company has established a strong foothold in the African market, with significant market shares in baby diapers (20.3%) and sanitary napkins (15.6%) [4][10]. - The report forecasts a revenue CAGR of 17.6% from 2025 to 2027, driven primarily by volume growth, with total sales expected to grow at approximately 21% [4][10]. - The company has a robust financial outlook, with net profit margins projected to average 21.2% from 2025 to 2027, despite a slight adjustment in gross margins [4][10]. Summary by Sections Financial Performance - Revenue is projected to grow from US$454 million in 2024 to US$739 million in 2027, with net profit expected to increase from US$95 million to US$155 million during the same period [2][4]. - The diluted EPS is forecasted to rise from US$0.19 in 2025 to US$0.25 in 2027 [2][4]. Market Positioning - Softcare has successfully transitioned from a trading company to a localized manufacturing giant, establishing production facilities in multiple African countries [7][8]. - The company has developed a differentiated brand matrix targeting various consumer segments, with its core brand "Softcare" positioned in the mid-to-high-end market [10][11]. Growth Strategy - The report highlights the company's strategy of leveraging its established distribution network and local manufacturing capabilities to expand into new emerging markets, including Latin America and Central Asia [4][32]. - The company has built a comprehensive distribution network with over 2,800 distribution points across Africa, Latin America, and Central Asia, enhancing its market penetration [34][36]. Product Categories - The primary revenue driver is the baby diaper segment, which contributes over 70% of total revenue, followed by significant growth in the baby pull-up pants and sanitary napkin categories [16][22]. - The sanitary napkin segment is expected to grow at a CAGR of 10.7% from 2024 to 2029, indicating strong future potential [46]. Regional Focus - The African market remains the cornerstone of Softcare's operations, contributing over 98% of its revenue, with significant growth opportunities identified in East and West Africa [28][29]. - The company is strategically expanding into Latin America and Central Asia, with revenue growth rates projected at 82.1% and 121.1% respectively for these regions [32][42].

Investment Rating - The report maintains an "Outperform" rating for Uni-President China Holdings [2] Core Views - Revenue growth is under pressure due to intensified competition, and a one-time equity impairment has negatively impacted profits [1][3] - The company achieved a revenue of RMB 31.7 billion in 2025, representing a year-on-year increase of 4.6% [3][13] - The beverage segment faced significant challenges in the second half of 2025, with revenue growth slowing to -5.8% due to price wars and competition [4][14] - The food business saw a gross margin increase to 27.1%, the highest in five years, driven by an optimized product mix and strong sales in snack categories [5][15] - The company has robust cash flow, with an estimated dividend yield of 7.1% for 2026, maintaining a 100% payout ratio [5][16] - Forecasts for 2026-2027 indicate revenue growth of 5.4% and 4.9%, with attributable net profit growth of 10.0% and 7.2% respectively [5][17] Financial Summary - Revenue projections for 2026 and 2027 are RMB 33.4 billion and RMB 35.1 billion, respectively, with net profit estimates of RMB 2.26 billion and RMB 2.42 billion [5][17] - The gross profit margin is expected to remain stable, with slight improvements projected for the coming years [10][17] - The company’s operating profit increased by 14.3% year-on-year to RMB 2.56 billion in 2025, with an operating margin of 8.1% [3][13]

Investment Rating - The report maintains an "Outperform" rating for JD Health International with a target price of HKD 71.07, while the current price is HKD 49.18 [2]. Core Insights - JD Health International's FY2025 revenue reached RMB 73.4 billion, representing a year-on-year growth of 26.3%, exceeding market expectations. The adjusted net profit was RMB 6.5 billion, up 36.3% year-on-year, with an adjusted net margin of 8.9%, the highest since the company's listing [3][13]. - The company has seen a consistent increase in revenue growth, with Q4 2025 revenue accelerating to RMB 21.0 billion, a 27.5% increase year-on-year, driven by strong performance in drugs, health supplements, and advertising [14]. - The growth in service revenue (3P) outpaced product revenue (1P), with service revenue reaching RMB 12.6 billion, a 34.1% increase year-on-year, indicating enhanced platform monetization capabilities [15]. - The expansion of offline pharmacy stores and the integration of medical insurance payment services into 29 cities are expected to improve service efficiency and enhance online-offline integration [16]. - The introduction of AI products, including "AI Jingyi" for consumers and "JD Zhuoyi" for hospitals, has created a comprehensive matrix that enhances user engagement and satisfaction [17]. Financial Projections - Revenue forecasts for 2026 and 2027 are set at RMB 86.9 billion and RMB 100.1 billion, respectively, with year-on-year growth rates of 18.3% and 15.2% [18]. - Adjusted net profit projections for 2026 and 2027 are RMB 6.5 billion and RMB 7.6 billion, reflecting a modest growth of 0.2% and a more robust 16.4% [18]. - The report anticipates a gross margin of 25.0% in 2026, with a gradual increase to 25.3% by 2027, indicating ongoing operational efficiency improvements [18]. Valuation - The DCF valuation method estimates the company's equity value at HKD 227.4 billion, corresponding to a target price of HKD 71.07 per share, maintaining the "Outperform" rating [19].

Liquidity Data - The US dollar index rose 1.3% to 98.96, briefly hitting a three-month high before easing[2] - Brent crude oil surged 9.3% to US$93.3 amid geopolitical tensions[2] - The 10-year US Treasury yield increased by 18.4 basis points to 4.13% due to rising inflation concerns[2] - Hong Kong equities saw net inflows of HK$8 billion from foreign investors during Feb 26–Mar 4, but reversed to net outflows of HK$29.9 billion during Mar 5–6[2] Sector Trends - Southbound capital significantly increased exposure to energy and banks while accelerating outflows from e-commerce and reducing holdings in biotech and insurance[2] - In the Hong Kong market, hard assets like oil & petrochemicals and non-ferrous metals led gains, while gold prices retreated[6] - The strategic revaluation of oil and gas resources is ongoing, with global oilfield service capital expenditures recovering[6] Risks and Economic Outlook - Risks include the potential for Fed rate cuts to fall short of expectations and uncertainties surrounding China's economic recovery and local government debt resolution[49] - A prolonged blockade in the Strait of Hormuz could drive oil prices towards US$100+ per barrel, with a potential nominal supply shock of up to 20 million barrels per day[34]

Investment Rating - The report maintains an "Outperform" rating for Hutchmed (China) Limited with a target price of HK$38.11, reflecting a potential upside from the current price of HK$22.18 [2][25]. Core Insights - Hutchmed reported a total revenue of USD 549 million for FY25, a decrease of 13% year-on-year, with oncology/immunology combined revenue at USD 290 million, down 21% year-on-year. This decline was attributed to a high base effect from a previous milestone payment and a drop in domestic sales of key products [3][18]. - The management expects a recovery in sales for FY26, projecting oncology/immunology revenue between USD 330 million and USD 450 million, which includes potential income from licensing the ATTC platform [3][19]. - The company is focusing on the development of its Antibody-Targeted Toxin Conjugate (ATTC) platform, with two products currently in global clinical development [6][19]. Financial Performance - For FY25, Hutchmed's net profit attributable to shareholders was USD 460 million, significantly boosted by a one-time gain of USD 480 million from the sale of a subsidiary [3][18]. - R&D expenses were USD 150 million, down 30% year-on-year, while SG&A expenses were USD 100 million, a decrease of 9% year-on-year [3][18]. - The company had cash and cash equivalents of USD 1.37 billion at the end of FY25, indicating a strong liquidity position [3][18]. Product Performance - Fruquintinib (ex-China) sales reached USD 370 million, up 26% year-on-year, driven by growth in the Japanese market and improved reimbursement coverage in Europe. However, domestic sales of Fruquintinib (China) fell to USD 76.9 million, down 11% year-on-year [19][23]. - The report highlights that the sales of core products in China showed signs of improvement in the second half of FY25, with Fruquintinib (China) revenue increasing by 29% quarter-on-quarter [19][23]. Clinical Development - HMPL-A251, a first-in-class ATTC targeting HER2, has shown promising anti-tumor activity comparable to existing therapies and is currently in a global Phase I/IIa clinical trial [20][24]. - HMPL-A580, another ATTC candidate targeting EGFR, has also entered clinical development, with a global Phase I trial initiated in March 2026 [21][22]. - Management plans to submit a global clinical trial application for a third ATTC candidate, HMPL-A830, within 2026 [22].

Investment Rating - The report does not explicitly state an investment rating for SJM Holdings, but it highlights significant declines in revenue and EBITDA, indicating potential concerns for investors. Core Insights - SJM Holdings reported a net revenue of HKD 6.5 billion for 25Q4, a decrease of 13% year-on-year, and an adjusted EBITDA of HKD 0.67 billion, down 32.4% year-on-year, with an EBITDA margin of 10.3%, down 3 percentage points year-on-year [1][7][11]. - The closure of satellite casinos has negatively impacted the company's gross gaming revenue (GGR), which reached HKD 6.66 billion, down 11.6% year-on-year, and the growth rate was below the industry average of +15% [3][10]. - The company's market share in 25Q4 was 10.4%, down from 11.8% in 25Q3 and 13.5% in 24Q4, indicating a decline in competitive positioning [5][12]. Summary by Sections Financial Performance - In 25Q4, SJM Holdings' net revenue was HKD 6.5 billion, down 13% year-on-year and 7.6% quarter-on-quarter. The gaming and non-gaming segments contributed HKD 6.04 billion and HKD 0.46 billion, respectively, with declines of 13.2% and 10.9% year-on-year [2][8]. - The adjusted EBITDA for 25Q4 was HKD 0.67 billion, reflecting a 32.4% year-on-year decline and a 23.8% quarter-on-quarter decline, with a margin of 10.3% [4][11]. Market Dynamics - The closure of satellite casinos has led to a slowdown in the company's GGR growth, with significant declines in the GGR from VIP and mass market segments [3][10]. - The company has undertaken acquisitions and property upgrades to consolidate market share, including properties on the Macau Peninsula, which are expected to attract customers previously served by satellite casinos [5][12]. Operational Adjustments - SJM Holdings has been reallocating gaming tables and operational resources from closed satellite casinos to its self-operated properties, aiming to mitigate the impact of the closures [5][12]. - The company plans to gradually close its satellite casinos, with the first closure occurring at the end of July 2025, and the remaining closures concentrated in the fourth quarter of 2025 [4][11].

Investment Rating - The report maintains an "Outperform" rating for Eastroc Beverage [2] Core Insights - Q1 revenue growth is expected to exceed expectations, driven by strong sales during the Spring Festival and effective pre-holiday business strategies [3][10] - The company has accelerated its internationalization strategy with a successful H-share listing and entry into the Southeast Asian market [11] - Short-term concerns regarding "sugar tax" rumors are not expected to impact the long-term value of the company, which continues to expand its distribution channels and product offerings [12] Financial Performance Summary - Revenue projections for 2025-2027 are RMB 20.99 billion, RMB 26.05 billion, and RMB 30.94 billion, representing year-on-year growth rates of 32.5%, 24.1%, and 18.7% respectively [5][13] - Net profit attributable to shareholders is expected to be RMB 4.6 billion, RMB 5.89 billion, and RMB 7.09 billion for the same period, with growth rates of 38%, 27.9%, and 20.3% [5][13] - The diluted EPS is projected to be RMB 8.9, RMB 11.3, and RMB 13.6 for 2025, 2026, and 2027 respectively [5][13] Strategic Initiatives - The company is focusing on expanding its distribution channels, including placing additional freezers and enhancing digital capabilities for better inventory management [12] - New product categories are being rapidly developed, with successful launches in electrolyte drinks and large-pack fruit tea targeting foodservice channels [12]